Investigational New Drugs

, Volume 30, Issue 6, pp 2377–2383 | Cite as

Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group

  • S. H. Park
  • M. H. Ryu
  • B. Y. Ryoo
  • S. A. Im
  • H. C. Kwon
  • S. S. Lee
  • S. R. Park
  • B. Y. Kang
  • Y. K. KangEmail author


Purpose To evaluated the efficacy and safety of sorafenib in patients with advanced gastrointestinal stromal tumors (GIST) who failed to previous standard treatments. Experimental Design Thirty-one patients with measurable metastatic GIST who failed both imatinib and sunitinib were accrued. Sorafenib was administered orally at 400 mg twice daily until disease progression or development of intolerance. The primary endpoint was disease control rate (response + stable disease, DCR) at 24 weeks. Results Sorafenib was well tolerated, with hand-foot skin reaction, fatigue, hypertension, and abdominal pain being the most frequent adverse events. The relative dose intensity of sorafenib during the first 6 months was >80%. Four patients achieved partial response (response rate 13%, 95% CI 1–25%), and 16 (52%) had stable disease. DCR at 24 weeks was measured as 36% (95% CI 19–52%). Median progression-free and overall survivals were 4.9 and 9.7 months, respectively. Progression-free survival of patients with prior use of nilotinib (P = .0085) and with primary genotypes other than KIT exon 11 mutation (P = .0341) was significantly shorter than that of patients without. Conclusions Sorafenib showed antitumor activity in this population of imatinib and sunitinib pretreated GIST. With sorafenib, about one third of patients can maintain disease control for more than 24 weeks.


Sorafenib Gastrointestinal stromal tumor 



We thank the patients who participated in this trial and the study coordinators, nurses and doctors who assisted with the research. This study was supported by a grant for GIST study from the Korean Gastric Cancer Association. Study drug (sorafenib) was kindly provided by Bayer-Schering Pharma Korea (Seoul, Korea).

Conflicts of interest

Yoon-Koo Kang received honorarium and research grant from Bayer. All other authors declare no potential conflicts of interest.


  1. 1.
    Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (New York, NY) 279(5350):577–580CrossRefGoogle Scholar
  2. 2.
    Savage DG, Antman KH (2002) Imatinib mesylate–a new oral targeted therapy. N Engl J Med 346(9):683–693PubMedCrossRefGoogle Scholar
  3. 3.
    Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480PubMedCrossRefGoogle Scholar
  4. 4.
    Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4):620–625PubMedCrossRefGoogle Scholar
  5. 5.
    Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127–1134PubMedCrossRefGoogle Scholar
  6. 6.
    Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26(4):626–632PubMedCrossRefGoogle Scholar
  7. 7.
    Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24(29):4764–4774PubMedCrossRefGoogle Scholar
  8. 8.
    Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PC, Brown M, Bertulli R, Judson IR (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23(24):5795–5804PubMedCrossRefGoogle Scholar
  9. 9.
    Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41(12):1751–1757PubMedCrossRefGoogle Scholar
  10. 10.
    Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338PubMedCrossRefGoogle Scholar
  11. 11.
    Kang YK, Kim KM, Sohn T, Choi D, Kang HJ, Ryu MH, Kim WH, Yang HK (2010) Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. J Korean Med Sci 25(11):1543–1552. doi: 10.3346/jkms.2010.25.11.1543 PubMedCrossRefGoogle Scholar
  12. 12.
    Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099–7109PubMedCrossRefGoogle Scholar
  13. 13.
    Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965–972PubMedCrossRefGoogle Scholar
  14. 14.
    Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, DeMatteo RP, Besmer P, Antonescu CR (2007) Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 13(16):4874–4881PubMedCrossRefGoogle Scholar
  15. 15.
    Huynh H, Lee JW, Chow PK, Ngo VC, Lew GB, Lam IW, Ong HS, Chung A, Soo KC (2009) Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther 8(1):152–159PubMedCrossRefGoogle Scholar
  16. 16.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247PubMedCrossRefGoogle Scholar
  17. 17.
    Gramza AW, Corless CL, Heinrich MC (2009) Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 15(24):7510–7518. doi: 10.1158/1078-0432.CCR-09-0190 PubMedCrossRefGoogle Scholar
  18. 18.
    Ryu MH, Lee JL, Chang HM, Kim TW, Kang HJ, Sohn HJ, Lee JS, Kang YK (2006) Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. Jpn J Clin Oncol 36(1):17–24. doi: 10.1093/jjco/hyi212 PubMedCrossRefGoogle Scholar
  19. 19.
    Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134. doi: 10.1056/NEJMoa060655 PubMedCrossRefGoogle Scholar
  20. 20.
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390. doi: 10.1056/NEJMoa0708857 PubMedCrossRefGoogle Scholar
  21. 21.
    Montemurro M, Schoffski P, Reichardt P, Gelderblom H, Schutte J, Hartmann JT, von Moos R, Seddon B, Joensuu H, Wendtner CM, Weber E, Grunwald V, Roth A, Leyvraz S (2009) Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 45(13):2293–2297. doi: 10.1016/j.ejca.2009.04.030 PubMedCrossRefGoogle Scholar
  22. 22.
    Sawaki A, Nishida T, Doi T, Yamada Y, Komatsu Y, Kanda T, Kakeji Y, Onozawa Y, Yamasaki M, Ohtsu A (2011) Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer. doi: 10.1002/cncr.26120
  23. 23.
    Kindler HL, Campbell NP, Wroblewski K, Maki RG, D'Adamo DR, Chow WA, Gandara DR, Antonescu C, Stadler WM, Vokes EE (2011) Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. J Clin Oncol 29, (suppl; abstr 10009)Google Scholar
  24. 24.
    Italiano A, Cioffi A, Coco P, Maki RG, Schoffski P, Rutkowski P, Le Cesne A, Duffaud F, Adenis A, Isambert N, Bompas E, Blay JY, Casali P, Keohan ML, Toulmonde M, Antonescu CR, Debiec-Rychter M, Coindre JM, Bui B (2011) Patterns of care, prognosis, and survival in patients with metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. Ann Surg Oncol. doi: 10.1245/s10434-011-2120-6
  25. 25.
    Reichardt P, Blay J, Gelderblom H, Schlemmer M, Demetri GD, Bin Bui N, McArthur GA, Yazji S, Hsu Y, Rutkowski P (2010) Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3. J Clin Oncol 28, (suppl; abstr 10017)Google Scholar
  26. 26.
    Yoon DH, Ryu MH, Ryoo BY, Beck M, Choi DR, Cho Y, Lee JL, Chang HM, Kim TW, Kang YK (2010) Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. Invest New Drugs. doi: 10.1007/s10637-010-9593-1
  27. 27.
    Guida T, Anaganti S, Provitera L, Gedrich R, Sullivan E, Wilhelm SM, Santoro M, Carlomagno F (2007) Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res 13(11):3363–3369. doi: 10.1158/1078-0432.CCR-06-2667 PubMedCrossRefGoogle Scholar
  28. 28.
    George S, von Mehren M, Heinrich MC, Wang Q, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Manola J, Yap JT, Van Den Abbeele AD, Solomon S, Fletcher JA, Demetri GD (2011) A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). J Clin Oncol 29, (suppl; abstr 10007)Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • S. H. Park
    • 1
  • M. H. Ryu
    • 2
  • B. Y. Ryoo
    • 2
  • S. A. Im
    • 3
  • H. C. Kwon
    • 4
  • S. S. Lee
    • 5
  • S. R. Park
    • 6
  • B. Y. Kang
    • 7
  • Y. K. Kang
    • 2
    Email author
  1. 1.Division of Hematology-Oncology, Department of MedicineSungkyunkwan University Samsung Medical CenterSeoulSouth Korea
  2. 2.Department of Oncology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea
  3. 3.Department of Internal MedicineSeoul National University HospitalSoeulSouth Korea
  4. 4.Department of Internal Medicine, Dong-A University College of MedicineDong-A University HospitalBusanSouth Korea
  5. 5.Division of Oncology, Department of Internal Medicine, Yonsei University College of MedicineYonsei University Health SystemSeoulSouth Korea
  6. 6.Research Institute and HospitalNational Cancer CenterGyeonggiSouth Korea
  7. 7.Department of Oncology/HematologyKyungpook National University HospitalDaeguSouth Korea

Personalised recommendations